Synlogic, Inc.

Synlogic, Inc. reported a net loss of $1.0 million for the fiscal year ended December 31, 2025, a significant improvement from the prior year's operating loss of $4.0 million, primarily due to a $3.0 million net gain from other income, largely driven by interest and investment income of $695K and a $2.3M change in the fair value of purchase warrant liability. The company generated no revenue and incurred total operating expenses of $4.0M, consisting of $3.5M in general and administrative costs, $476K in restructuring charges, and $43K in research and development. The company's strategic focus has shifted entirely to evaluating strategic alternatives, including a potential merger or sale, following the discontinuation of its lead clinical program in February 2024. As of the filing date, Synlogic is a non-operating public shell company with one employee, its common stock has been delisted from Nasdaq and trades on the OTCID Basic Market, and it has identified a material weakness in its internal control over financial reporting.

Key Takeaways